Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA
Eligible age
30+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
ABLE OA is a Health Canada authorized (phase II/III) trial \[Parent Control #: 263591\]. A multi-center, prospective, double-blinded, randomized, placebo-controlled adaptive trial to evaluate the efficacy of two minimally manipulated autologous cellular preparations i) bone marrow aspirate (BMA) injection; and, ii) combined lipoaspirate micronized (LAM) and leukocyte poor (LP) platelet-rich plasma (PRP) injections for the treatment of knee osteoarthritis (OA). BMA, LAM from lipoaspirate (LA), and LP-PRP from whole blood will be prepared using the Cervos Marrow Cellution™ Bone Marrow Aspiration System, Cervos LIPO-PRO™ Adipose Transfer System, and Cervos KEYPRP Platelet Separator System, respectively. Patient-reported outcome (PRO) measures will be collected using web- or paper-based questionnaires administered at baseline (pre-injection) as well as at 3, 6 and 12 months (post-injection). Blood, synovial fluid, and urine samples will be collected at baseline pre-injection and 6 months post-injection only.
Sponsor: University Health Network, Toronto
You may qualify if…
- ✓ Male or female at least 30 years of age at the time of screening
- ✓ Willingness and ability to comply with study procedures and visit schedules and able to follow oral and written instructions
- ✓ Signed consent for study participation
- ✓ Baseline NPRS ≥ 4 points
- ✓ Presence of chronic, symptomatic knee pain in at least one knee; if both knees are affected, the knee with greater severity will be selected for treatment
- ✓ KL grade 2 or 3 knee OA based on standing knee X-ray assessment
- ✓ Body mass index ≤ 30 kg/m2
You may not qualify if…
- ✕ Approved anti-inflammatory therapy injections (corticosteroid, Synvisc, PRP, nSTRIDE-Autologous Protein Solution) within the previous 6 months in the knee
- ✕ Major axial deviation (varus \>10°, valgus \>10°)
- ✕ Any concomitant knee lesion causing pain or effusion (i.e., ligamentous or meniscal injury, osteochondral lesion)
- ✕ Presence of clinically observed active infection in the index knee
- ✕ Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis secondary to other inflammatory diseases; chondrocalcinosis, Paget's disease, or villonodular synovitis
- ✕ Diagnosed with leukemia or other hematologic cancers, known presence of metastatic malignant cells, or ongoing or planned chemotherapeutic treatment
- ✕ Presence of venous or lymphatic stasis in the index leg
- ✕ A history of local anesthetic allergy
Source: ClinicalTrials.gov · NCT05517434 · last updated 2025-12-19